113 related articles for article (PubMed ID: 21638302)
1. Metabolism of thalidomide by human liver microsome cytochrome CYP2C19 is required for its antimyeloma and antiangiogenic activities in vitro.
Li Y; Jiang Z; Xiao Y; Li L; Gao Y
Hematol Oncol; 2012 Mar; 30(1):13-21. PubMed ID: 21638302
[TBL] [Abstract][Full Text] [Related]
2. [Effect of cytochrome CYP2C19 on the anti-myeloma activity of thalidomide in vitro].
Li YH; Hou J; Jiang H; Huang HM; Zhu R
Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):654-7. PubMed ID: 19176055
[TBL] [Abstract][Full Text] [Related]
3. [Antiangiogenic activity of thalidomide in vitro mediated by cytochrome CYP2C19].
Li YH; Hou J; Jiang H; Huang HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):102-6. PubMed ID: 19236757
[TBL] [Abstract][Full Text] [Related]
4. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
Kumar S; Raje N; Hideshima T; Ishitsuka K; Roccaro A; Shiraishi N; Hamasaki M; Yasui H; Munshi NC; Richardson P; Figg WD; Anderson KC
Leukemia; 2005 Jul; 19(7):1253-61. PubMed ID: 15858615
[TBL] [Abstract][Full Text] [Related]
5. Antimyeloma effects of resveratrol through inhibition of angiogenesis.
Hu Y; Sun CY; Huang J; Hong L; Zhang L; Chu ZB
Chin Med J (Engl); 2007 Oct; 120(19):1672-7. PubMed ID: 17935668
[TBL] [Abstract][Full Text] [Related]
6. Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.
Tokunaga E; Akiyama H; Soloshonok VA; Inoue Y; Hara H; Shibata N
PLoS One; 2017; 12(8):e0182152. PubMed ID: 28763493
[TBL] [Abstract][Full Text] [Related]
7. Antimyeloma efficacy of thalidomide in the SCID-hu model.
Yaccoby S; Johnson CL; Mahaffey SC; Wezeman MJ; Barlogie B; Epstein J
Blood; 2002 Dec; 100(12):4162-8. PubMed ID: 12393672
[TBL] [Abstract][Full Text] [Related]
8. s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line.
Liu WM; Strauss SJ; Chaplin T; Shahin S; Propper DJ; Young BD; Joel SP; Malpas JS
Hematol J; 2004; 5(3):247-54. PubMed ID: 15167912
[TBL] [Abstract][Full Text] [Related]
9. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H
J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
11. In vitro anti-proliferative and anti-angiogenic activities of thalidomide dithiocarbamate analogs.
El-Aarag BY; Kasai T; Zahran MA; Zakhary NI; Shigehiro T; Sekhar SC; Agwa HS; Mizutani A; Murakami H; Kakuta H; Seno M
Int Immunopharmacol; 2014 Aug; 21(2):283-92. PubMed ID: 24859059
[TBL] [Abstract][Full Text] [Related]
12. Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells.
Yata K; Otsuki T; Kurebayashi J; Uno M; Fujii T; Yawata Y; Takata A; Hyodoh F; Sugihara T
Int J Oncol; 2003 Jan; 22(1):165-73. PubMed ID: 12469200
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
Vacca A; Scavelli C; Montefusco V; Di Pietro G; Neri A; Mattioli M; Bicciato S; Nico B; Ribatti D; Dammacco F; Corradini P
J Clin Oncol; 2005 Aug; 23(23):5334-46. PubMed ID: 15939924
[TBL] [Abstract][Full Text] [Related]
14. Palliative oncology: thalidomide.
Prommer EE
Am J Hosp Palliat Care; 2010 May; 27(3):198-204. PubMed ID: 19843880
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antiangiogenic activity of tetrandrine combined with Endostar on the human umbilical vein endothelial cell model.
Qian X; Yan B; Zhou X; Xie L; Wei J; Li R; Yu L; Liu B
Cancer Biother Radiopharm; 2013 Jun; 28(5):385-90. PubMed ID: 23682584
[TBL] [Abstract][Full Text] [Related]
16. α-Tocopherol suppresses antiangiogenic effect of δ-tocotrienol in human umbilical vein endothelial cells.
Shibata A; Nakagawa K; Tsuduki T; Miyazawa T
J Nutr Biochem; 2015 Apr; 26(4):345-50. PubMed ID: 25662730
[TBL] [Abstract][Full Text] [Related]
17. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Rajkumar SV; Witzig TE
Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
[TBL] [Abstract][Full Text] [Related]
18. [Effect of CYP2C19 gene polymorphism on efficacy of thalidomide-based regimens for the treatment of multiple myeloma].
Li YH; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):651-4. PubMed ID: 18399167
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide and multiple myeloma serum synergistically induce a hemostatic imbalance in endothelial cells in vitro.
Gao Y; Ma G; Liu S; Teng Y; Wang Y; Su Y
Thromb Res; 2015 Jun; 135(6):1154-9. PubMed ID: 25840743
[TBL] [Abstract][Full Text] [Related]
20. [Effect of 2-methoxyestradiol on proliferation and apoptosis of myeloma cell lines].
Gao WR; Hou J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Apr; 13(2):293-7. PubMed ID: 15854295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
